Abstract
It has been claimed that early use of statins in acute coronary syndromes (ACS) protects patients against recurrent ischemic events. This protective effect takes place as early as 4 months after treatment initiation in non-ST elevation ACS, as reported in the MIRACL trial. Mechanisms such as improvement in endothelial function and inflammation are possible explanations for this early effect. These findings have been used to propose statins as part of the acute phase therapy. However, the use of statins during hospitalization is an unresolved issue, because there is a lack of evidence regarding the benefit of initiating therapy in the acute phase. Most randomized trials included patients after several days of the index event and did not report in-hospital outcome. This review critically discusses the use of statins in ACS and the level of evidence regarding their beneficial effect in acute phase treatment.
Keywords: Statin therapy, statins, acute coronary syndromes, unstable angina, acute myocardial infarction, acute phase
Current Vascular Pharmacology
Title: Is There a True Beneficial Effect of Statin Therapy in the Acute Phase of Unstable Angina or Myocardial Infarction?
Volume: 5 Issue: 3
Author(s): Luis C.L. Correia
Affiliation:
Keywords: Statin therapy, statins, acute coronary syndromes, unstable angina, acute myocardial infarction, acute phase
Abstract: It has been claimed that early use of statins in acute coronary syndromes (ACS) protects patients against recurrent ischemic events. This protective effect takes place as early as 4 months after treatment initiation in non-ST elevation ACS, as reported in the MIRACL trial. Mechanisms such as improvement in endothelial function and inflammation are possible explanations for this early effect. These findings have been used to propose statins as part of the acute phase therapy. However, the use of statins during hospitalization is an unresolved issue, because there is a lack of evidence regarding the benefit of initiating therapy in the acute phase. Most randomized trials included patients after several days of the index event and did not report in-hospital outcome. This review critically discusses the use of statins in ACS and the level of evidence regarding their beneficial effect in acute phase treatment.
Export Options
About this article
Cite this article as:
Luis C.L. Correia , Is There a True Beneficial Effect of Statin Therapy in the Acute Phase of Unstable Angina or Myocardial Infarction?, Current Vascular Pharmacology 2007; 5 (3) . https://dx.doi.org/10.2174/157016107781024127
DOI https://dx.doi.org/10.2174/157016107781024127 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mitochondrial Uncoupler Proteins
Current Enzyme Inhibition Antioxidants in Treating Pathologies Involving Oxidative Damage: An Update on Medicinal Chemistry and Biological Activity of Stobadine and Related Pyridoindoles
Current Medicinal Chemistry Hyperglycemia and Perioperative Glucose Management
Current Pharmaceutical Design Editorial [Hot Topic:Modifying Cardiovascular Risk Factors: Newer Insights and Preventive Measures (Executive Editor: Aurelio Leone)]
Current Pharmaceutical Design The Cellular Effects of Carbon Monoxide in the Airway
Current Molecular Medicine Renin Angiotensin System as a Regulator of Cell Volume. Implications to Myocardial Ischemia
Current Cardiology Reviews Is there a Role for Oral Triple Therapy in Patients with Acute Coronary Syndromes Without Atrial Fibrillation?
Current Vascular Pharmacology Host Innate Immune Responses to Microbial Pathogens
Current Vascular Pharmacology Neuregulin1 as Novel Therapy for Heart Failure
Current Pharmaceutical Design Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib
Current Medicinal Chemistry The Pathogenic Subpopulation of Th17 Cells in Obesity
Current Pharmaceutical Design Beneficiary and Adverse Effects of Phytoestrogens: A Potential Constituent of Plant-based Diet
Current Pharmaceutical Design Clinical Applications of Cardiovascular Magnetic Resonance
Current Pharmaceutical Design TRP Channels in Vascular Disorders
Current Topics in Medicinal Chemistry Introduction: P2 Receptors
Current Topics in Medicinal Chemistry Emerging Therapies for Diabetic Neuropathy: A Clinical Overview
Current Diabetes Reviews Relationship between Augmentation Index and Wall Thickening Fraction during Hypotension in an Animal Model of Myocardial Ischemia-Reperfusion and Heart Failure
Current Hypertension Reviews Clinical Trials for Acute Kidney Injury: Design Challenges and Possible Solutions
Current Drug Targets Safety of Cabergoline in the Management of Pituitary Prolactin-Induced Symptoms with Patients Treated with Atypical Neuroleptics
Current Drug Safety The Role of Fatty Acids in the Regulation of Cerebral Vascular Function and Neuroprotection in Ischemia
CNS & Neurological Disorders - Drug Targets